Suppr超能文献

低密度脂蛋白受体相关蛋白(LRP)在大鼠体内重组单链尿激酶型纤溶酶原激活剂的血浆清除及肝脏摄取中的作用

The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats.

作者信息

van der Kaaden M E, Rijken D C, Kruijt J K, van Berkel T J, Kuiper J

机构信息

Division of Biopharmaceutics, Sylvius Laboratory, Leiden/Amsterdam Center for Drug Research, University of Leiden, The Netherlands.

出版信息

Thromb Haemost. 1997 Apr;77(4):710-7.

PMID:9134648
Abstract

Urokinase-type plasminogen activator (u-PA) is used as a thrombolytic agent in the treatment of acute myocardial infarction. In vitro, recombinant single-chain u-PA (rscu-PA) expressed in E.coli is recognized by the Low-Density Lipoprotein Receptor-related Protein (LRP) on rat parenchymal liver cells. In this study we investigated the role of LRP in the liver uptake and plasma clearance of rscu-PA in rats. A preinjection of the LRP inhibitor GST-RAP reduced the maximal liver uptake of 125I-rscu-PA at 5 min after injection from 50 to 30% of the injected dose and decreased the clearance of rscu-PA from 2.37 ml/min to 1.58 ml/min. Parenchymal, Kupffer and endothelial cells were responsible for 40, 50 and 10% of the liver uptake, respectively. The reduction in liver uptake of rscu-PA by the preinjection of GST-RAP was caused by a 91% and 62% reduction in the uptake by parenchymal and Kupffer cells, respectively. In order to investigate the part of rscu-PA that accounted for the interaction with LRP, experiments were performed with a mutant of rscu-PA lacking residues 11-135 (= delta 125-rscu-PA). Deletion of residues 11-135 resulted in a 80% reduction in liver uptake and a 2.4 times slower clearance (0.97 ml/min). The parenchymal, Kupffer and endothelial cells were responsible for respectively 60, 33 and 7% of the liver uptake of 125I-delta 125-rscu-PA. Preinjection of GST-RAP completely reduced the liver uptake of delta 125-rscu-PA and reduced its clearance to 0.79 ml/min. Treatment of isolated Kupffer cells with PI-PLC reduced the binding of rscu-PA by 40%, suggesting the involvement of the urokinase-type Plasminogen Activator Receptor (u-PAR) in the recognition of rscu-PA. Our results demonstrate that in vivo LRP is responsible for more than 90% of the parenchymal liver cell mediated uptake of rscu-PA and for 60% of the Kupffer cell interaction. It is also suggested that u-PAR is involved in the Kupffer cell recognition of rscu-PA.

摘要

尿激酶型纤溶酶原激活剂(u-PA)在急性心肌梗死的治疗中用作溶栓剂。在体外,大肠杆菌中表达的重组单链u-PA(rscu-PA)可被大鼠实质肝细胞上的低密度脂蛋白受体相关蛋白(LRP)识别。在本研究中,我们调查了LRP在大鼠肝脏摄取和rscu-PA血浆清除中的作用。预先注射LRP抑制剂GST-RAP可使注射后5分钟时125I-rscu-PA的最大肝脏摄取量从注射剂量的50%降至30%,并使rscu-PA的清除率从2.37 ml/min降至1.58 ml/min。实质细胞、库普弗细胞和内皮细胞分别占肝脏摄取量的40%、50%和10%。预先注射GST-RAP导致rscu-PA肝脏摄取量减少,这是由于实质细胞和库普弗细胞摄取量分别减少了91%和62%。为了研究rscu-PA中与LRP相互作用的部分,我们用缺乏11-135位残基的rscu-PA突变体(=δ125-rscu-PA)进行了实验。缺失11-135位残基导致肝脏摄取量减少80%,清除率减慢2.4倍(0.97 ml/min)。实质细胞、库普弗细胞和内皮细胞分别占125I-δ125-rscu-PA肝脏摄取量的60%、33%和7%。预先注射GST-RAP可完全降低δ125-rscu-PA的肝脏摄取量,并将其清除率降至0.79 ml/min。用磷脂酰肌醇特异性磷脂酶C(PI-PLC)处理分离的库普弗细胞可使rscu-PA结合减少40%,提示尿激酶型纤溶酶原激活剂受体(u-PAR)参与rscu-PA的识别。我们的结果表明,在体内,LRP负责超过90%的由实质肝细胞介导的rscu-PA摄取以及60%的库普弗细胞相互作用。还提示u-PAR参与库普弗细胞对rscu-PA的识别。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验